About MannKind

MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration, is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.  More >

 

                    follow me on twitter       find us on facebook

 
For more information about AFREZZA, please visit www.Afrezza.com.

 Spotlight

 

2016 Annual Shareholders Meeting Video
click here

 

CEO Spotlight - Open Letter from Matt 
To view letter click here

News & Events

   
Jun 12, 2016 MannKind Announces Late-Breaking Data Demonstrating Faster Onset and Shorter Duration... More >
Jun 10, 2016 MannKind Announces Collaboration with JDRF More >
May 09, 2016 MannKind Corporation Reports 2016 First Quarter Financial Results More >